Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use
暂无分享,去创建一个
J. Izopet | S. Raymond | P. Delobel | K. Sauné | N. Jeanne | R. Carcenac | C. Lefebvre | M. Cazabat | F. Nicot | O. Delfour
[1] Xian-Ming Pan,et al. HIV coreceptor tropism determination and mutational pattern identification , 2016, Scientific Reports.
[2] J. Izopet,et al. Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism , 2015, Scientific Reports.
[3] Bie M. P. Verbist,et al. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. , 2015, Journal of virological methods.
[4] O. Mor,et al. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. , 2015, Journal of virological methods.
[5] A. Hughes,et al. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq , 2014, Retrovirology.
[6] P. Harrigan,et al. “Deep” Sequencing Accuracy and Reproducibility Using Roche/454 Technology for Inferring Co-Receptor Usage in HIV-1 , 2014, PloS one.
[7] David L. Robertson,et al. Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism , 2014, Antimicrobial Agents and Chemotherapy.
[8] P. Massip,et al. Genotypic Prediction of HIV-1 CRF01-AE Tropism , 2012, Journal of Clinical Microbiology.
[9] J. Archer,et al. Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism , 2012, PloS one.
[10] R. Kagan,et al. A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.
[11] M. Jensen,et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] P. Massip,et al. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing , 2011, AIDS.
[13] P. Massip,et al. Genotypic prediction of HIV-1 subtype D tropism , 2011, Retrovirology.
[14] V. Calvez,et al. Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.
[15] Alexander Thielen,et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. , 2011, The Journal of infectious diseases.
[16] Thomas Lengauer,et al. Improved prediction of HIV‐1 coreceptor usage with sequence information from the second hypervariable loop of gp120. , 2010, The Journal of infectious diseases.
[17] P. Massip,et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[18] John Archer,et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing , 2009, AIDS.
[19] Anders Karlsson,et al. Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.
[20] L. Cuzin,et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism , 2008, AIDS.
[21] Natalia Chueca,et al. Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes , 2008, Journal of Clinical Microbiology.
[22] Thomas Lengauer,et al. Bioinformatics prediction of HIV coreceptor usage , 2007, Nature Biotechnology.
[23] M. Ronaghi,et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.
[24] Christophe Pasquier,et al. Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies , 2007, Journal of Clinical Microbiology.
[25] Tobias Sing,et al. Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.
[26] H. Schuitemaker,et al. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. , 1993, Science.
[27] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[28] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.